Mental Clarity & Flow Balance

1. Post‑Stroke Neurological Disorders (dysphagia, cognitive impairment, PSD)

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

Systematic review & meta‑analysis of RCTs

A 2021 systematic review and meta‑analysis evaluated Di‑Tan Decoction for post‑stroke neurological disorders (PNSD), including post‑stroke dementia, cognitive impairment, and other sequelae.

• Included randomized clinical trials comparing DTD (alone or adjunctive) to conventional treatment.

• DTD was associated with significant improvement in neurological scales and cognitive indices (e.g., MMSE, neurologic deficit scores) compared with control therapies.

• The pooled results suggested better overall response rates and functional outcomes with DTD‑containing regimens, although trial quality and reporting were variable and mostly from Chinese literature.

• No serious adverse events clearly attributable to DTD were reported.

The authors concluded that DTD may be a promising adjunct for post‑stroke neurological disorders, but more rigorous, larger, multicenter RCTs are needed.

RCT: DTD + electroacupuncture + swallowing rehab in post‑stroke dysphagia (PSD)

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

A 2022 randomized controlled trial evaluated the effect of adding Di‑Tan Decoction (DTD) and/or electroacupuncture (EA) to standard swallowing rehabilitation training (SRT) in patients with post‑stroke dysphagia (PSD).

• Four groups:

  1. SRT alone,

  2. SRT + DTD,

  3. SRT + EA,

  4. SRT + DTD + EA.

• Primary outcomes: Functional Oral Intake Scale (FOIS), Standardized Swallowing Assessment (SSA), and Videofluoroscopic Swallowing Study (VFSS) scores.

• Results:

  • All groups improved, but SRT + DTD + EA showed the largest improvement in swallowing function scores versus SRT alone.

  • Both DTD and EA individually improved swallowing more than SRT alone, but DTD + EA was superior to either adjunct alone.

  • No serious treatment‑related adverse events occurred.

This study supports DTD (especially combined with EA) as an effective adjunct for post‑stroke dysphagia in phlegm‑heat / phlegm‑turbidity patterns.

Alzheimer’s disease and dementia

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

A 2015 review of Chinese herbal medicine Di‑Tan Decoction in Alzheimer’s disease (AD) summarizes modern clinical and basic research.

• DTD has long been used in TCM for symptoms now labeled as dementia/AD (memory loss, disorientation, apathy, speech difficulty) under the pattern of Phlegm turbidity obstructing the orifices.

• Clinical reports (mostly small, non‑blinded or low‑quality) indicate that DTD can improve cognitive scores (MMSE, ADL), sleep, and behavioral disturbances in AD or vascular dementia patients when used as add‑on therapy to conventional drugs.

• Experimental work shows DTD may reduce cerebral infarct volume, protect the blood–brain barrier, and improve cerebral microcirculation in ischemic brain models, providing mechanistic support for stroke and dementia indications.

Overall, the AD/dementia evidence is promising but preliminary and methodologically limited.